跳至主要内容
临床试验/CTRI/2018/01/011309
CTRI/2018/01/011309尚未招募未知

A randomised, double blinded, comparative study to investigate the effectiveness & safety of Me-Cal in osteoporosis patients as compared to standard calcium supplement containing calcitrol, calcium and zinc.

SG PHYTO PHARMA PVT LTD0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Patients complaining of classical symptoms of
  • joint pain, pain in the bones etc. which will
  • be confirmed later by the BMD-test with BMD
  • score below -1.
  • 2. Patient agrees not to use any other calcium
  • supplement for osteoporosis other than what is
  • provided by the study.
  • 3. Patient agrees to written informed consent.
  • 4. Patient willing to participate in the study
  • for 12 weeks.
  • 5. Patient who has not participated in any
  • clinical study in last 30 days.

排除标准

  • 1.Planning to conceive, pregnant and lactating mothers.
  • 2. Patient under osteoporosis treatment.
  • 3. Patients suffering from heart disease.
  • 4. Patients with severe renal impairment.
  • 5. Patient with known metabolic bone disease such
  • as osteogenesis imperfecta, or currently
  • healing fractures of lumbar spine, hips or
  • 6. Patient on current treatment with steroids or
  • chemotherapy.
  • 7. History of malignancy
  • 8. History of hypersensitivity to any of the investigational drugs.
  • 9. History of psychiatric disorder that may impair the ability of subjects to provide written informed consent
  • 10. Any medical condition, where the investigator feels participation in the study could be detrimental to the subjects overall well-being.

研究者

发起方
SG PHYTO PHARMA PVT LTD

相似试验